State health official: all‑payers claims dataset is de‑identified; privacy concerns surface in committee
Loading...
Summary
Minnesota Department of Health testified the all‑payers claims data are de‑identified and subject to statutory guardrails and data‑use agreements, but several senators pressed the committee for a fuller discussion of re‑identification risks and oversight.
A focused exchange in the Minnesota Senate Health and Human Services Committee turned to the state’s all‑payers claims dataset and whether data purchases could be re‑identified or bought by foreign actors.
Stefan Guillermoistern, who introduced himself as director of the Health Economics Program at the Minnesota Department of Health, told the committee that the datasets are de‑identified and that the 2023 statute charged MDH with establishing a fee schedule and an advisory process to determine whether projects served the public interest and whether data users were qualified and bound by enforceable data‑use agreements. "These data are de identified," he stated, adding that statute prohibits re‑identification and commercial resale that violates data‑use agreements.
Senator Liske pressed the panel, citing long‑standing research showing simple combinations of demographic fields can enable re‑identification in some contexts. She offered an amendment (A‑15) to remove two sections authorizing some broader data access and fee authority; the committee held a roll call and did not adopt A‑15 (4 yes, 5 no).
Why it matters: All‑payers claims data can support policy analysis of costs, utilization and outcomes across public and private payers, but the committee’s exchange shows continuing concern over de‑identification limits, secondary uses and enforcement when datasets leave state custody.
Testimony and safeguards MDH described multiple guardrails: an advisory group to approve public interest uses, qualification standards for recipients, legally enforceable data‑use agreements and a fee schedule placed in statute. MDH and the sponsor told members the 2023 law already imposed restrictions and a process intended to reduce re‑identification risk.
Remaining questions and next steps Members who supported A‑15 said the committee should pause and convene more extensive discussion about technical re‑identification risks and enforcement remedies. Sponsors and staff argued the statute and department processes provide safeguards and that continued oversight by the advisory group and clear contractual restrictions are the appropriate tools. The committee voted down the removal amendment; staff and sponsors indicated they would continue stakeholder engagement and finalize fee and access rules.
